Kuopio, Finland – Experimentica Ltd., a recognized ophthalmic CRO known for its advanced preclinical ocular models and imaging platforms, announces a major strategic investment in the establishment of a Good Laboratory Practice (GLP)-compliant test facility to provide GLP safety and toxicology studies for preclinical development of ophthalmic drugs and related technologies. This marks a significant milestone in the company’s service offering.

“This is a major and strategically important milestone in Experimentica’s history. It reflects our drive to move forward and grow our capabilities and service offering. At the same time, we recognize that this is a significant undertaking for our entire organization as we are stepping into emerging and, in many ways, ambitious areas that are new to us”, says the Managing Director, Jukka Puoliväli. “Importantly, every action we take to advance the GLP program will further strengthen us as an organization and, in parallel, elevate the quality of our non-GLP operations.”

Expanding into GLP toxicology

For more than a decade, Experimentica has supported companies developing ophthalmic drugs globally through specialized in vitro and in vivo models. The new GLP test facility will be built on this scientific foundation, expanding the company’s ability to conduct regulated safety assessments for ophthalmic therapeutics. Upcoming GLP capabilities will cover multiple administration routes and therapeutic modalities in both rodent and non-rodent species (mouse, rat, rabbit).

“What began as a small, passionate team of four has grown into a thriving family of over fifty talented professionals committed to scientific excellence in advancing preclinical ocular drug discovery. The implementation of GLP services marks an exciting new chapter in our journey toward global leadership in the field,” noted the Founder and Executive Chairman Dr. Giedrius Kalesnykas.

Supporting sponsors across development phases

By adding GLP capabilities to its existing non-GLP research offering, Experimentica aims to ensure a continuous and predictable transition for its clients from exploratory research toward regulatory submissions.

“This investment directly addresses one of the most common bottlenecks we hear from clients: the need to switch CROs when moving from non-GLP research into IND-enabling studies. Experimentica will be able to support sponsors seamlessly across that transition, from early exploratory work through to GLP-regulated safety and toxicology. If you are approaching this stage, we encourage you to come and meet us at upcoming events to discuss how we can support you,” says Guillaume Demarne, Chief Business Officer of Experimentica.

The establishment of the GLP-compliant test facility in Kuopio, Finland, is co-funded by the European Union.

About Experimentica Ltd.

Experimentica Ltd. is a leading contract research organization dedicated to developing and managing preclinical models for ophthalmic indications. With proprietary laboratories in Kuopio, Finland and Vilnius, Lithuania, and an industry-leading portfolio, the company supports the discovery and development of new therapies by offering comprehensive research solutions to the pharmaceutical and biotech companies.

More information on Experimentica's GLP studies
Jukka Puoliväli

Jukka Puoliväli

, PhD

Managing Director, Experimentica Oy